Abstract:We herein report the identification, structural optimization, and structure–activity relationship of thieno[2,3-d]pyrimidine derivatives as a novel kind of selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitors. N-(4-Chloro-3-(trifluoromethyl)phenyl)-4-(6-(4-(4-methylpiperazin-1-yl)phenyl)thieno[2,3-d]pyrimidin-4-yl)piperazine-1-carboxamide (38k) was the most potent VEGFR3 inhibitor (IC50 = 110.4 nM) among developed compounds. Compared with VEGFR1 and VEGFR2, VEGFR3 was approximately 100 times more selective. Here, compound 38k significantly inhibited proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells by inactivating the VEGFR3 signaling pathway. Additionally, 38k induced cell apoptosis and a prolonged G1/S-phase in MDA-MB-231 and MDA-MB-436 cells. It also presented acceptable pharmacokinetic characteristics in Sprague-Dawley (SD) rats with an oral bioavailability of 30.9%. In the xenograft model in vivo, 38k effectively inhibited breast cancer growth by suppressing the VEGFR3 signaling pathway. 38k pronouncedly resisted the formation of pulmonary metastatic nodules in mice. Collectively, 38k may be a promising therapeutic agent of metastatic breast cancer.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00678.Schematic illustration of the chemical screening process; identification of novel VEGFR3 inhibitor hits in an in-house library containing 3500 bioactive compounds; chemical structures of the eight initial hits; IC50 values of hit compounds 1–8 toward VEGFR3; effect of 38k on HDLEC cell survival; cells were stimulated with VEGFA (10 ng/mL) and VEGF-D (300 ng/mL) in the presence of increasing 38k doses; selectivity profiling of compound 38k at 1000 nM against 412 kinases; NMR data of all compounds (PDF)Molecular formula strings and the associated biochemical and biological data (CSV)VEGFR3 homology model in the PDB format and docking poses for 11 and 38k (ZIP)This article has not yet been cited by other publications.

An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding

Phage‐derived Fully Human Antibody Scfv Fragment Directed Against Human Vascular Endothelial Growth Factor Receptor 2 Blocked Its Interaction with VEGF

Inhibition Of Angiogenesis By A Novel Neutralizing Antibody Targeting Human Vegfr-3

Dual Blockade of Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (FGF-2) Exhibits Potent Anti-Angiogenic Effects.

A Murine–human Chimeric IgG Antibody Against Vascular Endothelial Growth Factor Receptor 2 Inhibits Angiogenesis in Vitro

Generation and Characterization of a Novel Human IgG1 Antibody Against Vascular Endothelial Growth Factor Receptor 2

The antiangiogenic activity of a soluble fragment of the VEGFR extracellular domain.

A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation

Evaluation of the binding and anti-angiogenic capacity of anti-vascular endothelial growth factor receptor 2 nanobody (anti-vegfr2 nanobody)

Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2

Generation and characterization of a human nanobody against VEGFR-2

A Human IgG-like Bispecific Antibody Co-targeting Epidermal Growth Factor Receptor and the Vascular Endothelial Growth Factor Receptor 2 for Enhanced Antitumor Activity.

Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer

Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.

A Non-immunogenic Bivalent d -Protein Potently Inhibits Retinal Vascularization and Tumor Growth

VEGFR2-targeted Antibody Fused with IFNαmut Regulates the Tumor Microenvironment of Colorectal Cancer and Exhibits Potent Anti-Tumor and Anti-Metastasis Activity

Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy

Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer

Screening and anti-angiogenesis activity of Chiloscyllium plagiosum anti-human VEGFR2 single-domain antibody

VEGFR2-targeted antibody fused with IFN mut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity